News

Pharma News

Emdeon and PDX Embark on Patient Medication History Initiative

NASHVILLE, Tenn., Oct. 1, 2012 /PRNewswire/ -- Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, and PDX – NHIN (www.pdxinc.com), a leader in pharmacy management solutions and services for retail pharmacy for almost thirty years, today jointly announced plans for an initiative designed to improve...

ValueCentric and PDX-Rx.com Expand Alliance

ORCHARD PARK, NY--(Marketwire -04/23/12)- ValueCentric LLC, the leader in connected healthcare intelligence and PDX-Rx.com, the leading pharmacy technology provider to the retail pharmacy segment, today announced that the companies have expanded their existing relationship to include data sharing and reporting that will link ValueCentric's healthcare intelligence platform and comprehensive industry channel data with significantly expanded store level prescription data offered through...

New Technology Can Find New Uses for Old Drugs

A computer program that analyzes drug data and genetic information could help discover new uses for medications already on the market, according to two studies. For the National Institute of Health-funded research, Stanford University scientists identified possible drug-disease matches for 53 of the 100 diseases analyzed. Researchers noted that re-purposing existing medications could reduce drug development requirements and costs.

Allergra Now an Over-the-Counter Medication

Sanofi-Aventis and its U.S. consumer healthcare division Chattem last week announced the Food and Drug Administration has approved the Allegra (fexofenadine HCl) family of allergy medication products for over-the-counter use in adults and children 2 years of age and older.

Pharmaceutical Market to Reach $880 Billion Value

NORWALK, Conn. - The global pharmaceutical market will reach a value of $880 billion next year, according to a report by a healthcare-market research firm. Read more on "IMS Health projects growth for Rx market"

Pharmaceutical Companies Use EHRs to Improve Clinical Trial Recruitment

A group of pharmaceutical companies, academic medical centers and healthcare organizations launched a new collaborative that aims to tap into electronic health records (EHR) to bolster clinical trial recruitment. Members of the collaborative, called Partnership to Advance Clinical electronic Research (PACeR), include Pfizer, Johnson & Johnson and Merck & Co.

MTM Programs Save Money

Today's New York Times features an article, "For Forgetful, Cash Helps the Medicine Go Down, 6/13/10", which focuses on the costs associated with medication non-adherence. The article also highlights pharmacy's victory in expanding medication therapy management (MTM) services for Medicare patients in the new healthcare reform law. The New York Times on the Web (Free Registration...

Employer healthcare costs expected to rise 9% in 2011

Rising healthcare costs not good news for Employers. Read more on "Employer healthcare costs expected to rise 9% in 2011" 

Bayer Releases iPhone App

SAN ANTONIO - German drug maker Bayer HealthCare Pharmaceuticals has created an iPhone application that it called the first developed for patients using a specific multiple sclerosis medication, Bayer said last week. Read...

Longtime Gout Drug Allopurinol Now Discovered to Treat Angina

Allopurinol, a drug used for more than 40 years to treat gout, may be an inexpensive generic alternative to newer medications used to treat angina, according to a study in The Lancet. Electrocardiograms showed the drug enabled hearts to work for longer periods before showing signs of oxygen deprivation. Read more on "Cheap gout drug proves useful for heart...

Why Don't Patients Fill Prescriptions? A Study Examining Primary Non-adherence

The authors from Boston's Brigham and Women's and Massachusetts General Hospitals assessed primary nonadherence, or failure to fill new prescriptions, to identify factors that predict nonadherence.  Read more on "Why Don't Patients Fill Prescriptions? A Study Examining Primary Non-adherence" (Medscape Today registration required.)

Post-reform, pharma will market to payers

In all the post-game analysis of how healthcare reform will affect the drugs business, one new theme has emerged: The legislation's impact on pharma marketing. Apparently, experts think reform will end up giving insurance companies and other payers a lot more influence over which drugs are prescribed. And if payers are the ones in the driver's seat, then drugmakers' selling strategies will have to be overhauled. Goodbye, doctor detailing; hello, payer...

PhRMA, BIO, GPhA weigh in on healthcare-reform bill passage

“The existing barriers to quality health care simply are not acceptable,” an organization statement read. “Today’s important and historic vote in the House will help to expand healthcare coverage and services to tens of millions of Americans who are uninsured and often forced to forego needed medical treatments.” Read more on...

Number of unfilled scrips approaches 15%

Congratulations! Your quality products, savvy advertising and canny sales reps have put new prescriptions in patients' hands. But what if those scrips never make it out of a pharmacy? That's exactly what's happening--more often than ever. According to a new report, the number of prescriptions never picked up from the pharmacy grew by 24 percent in 2009--and it's up a full 68 percent since 2006. A full 8.6 percent of new prescriptions for branded meds are abandoned at the drugstore,...

Why do Americans pay more for their meds?

Why do Americans pay so much for their pharmaceuticals? That's the question posed by Sen. Herb Kohl, a Democrat and chairman of the Senate Special Committee on Aging, who has written to the world's top drugmakers to demand an explanation. "Americans pay, on average, twice as much as people in other industrialized countries," Chairman Kohl states in the letter. "While I firmly believe that drug quality should not be sacrificed for cost, the large discrepancies in the cost of...

IMS to Big Pharma: Get moving!

Is it possible that Big Pharma isn't moving fast enough into emerging markets? That's the implication of a new report from IMS Health. According to the market research firm, 17 "pharmerging" markets will account for almost half of the growth in drug sales by 2013, up from 37 percent last year. By then, emerging markets will make up 21 percent of total pharma sales. The fastest-growing is China, which will account for $40 billion in additional sales. Brazil, Russia and India are following...

Have pharma promos gone too commercial?

Over the past few years, we've seen some drugmakers choose new executives from the ranks of consumer-products companies. Joe Jiminez, Novartis' new chief, says his experience hawking Heinz ketchup helps him manage more effectively in the pharma world. Pfizer CEO Jeff Kindler is famous for his status as a former McDonald's executive. So if pharma's going to borrow talent from consumer goods, why not borrow consumer-goods marketing? A New York Times story takes a look at one...

For tough 2010, pharma cuts billions from R&D

Over the last week or so, we've seen three Big Pharmas announce big changes to their research operations--and those big changes include big job cuts. Big cost savings, too, the companies say. The new cuts are hitting the news along with pharma earnings, which, so far, have been more than respectable. It's 2010 that everyone's worried about. Analysts haven't been cheering with delight at any Big Pharma sales-and-profits forecast for the year. AstraZeneca expects earnings to...

Investors should remember the patent cliff

For pharmacy retailers, the loss of patent protection for a slew of blockbuster drugs over the next decade is a double-edged sword. Read more in "Investors should remember the patent cliff"

Pharma Comes Under Fire for Jump in Rx Prices

A subcommittee of the House Energy and Commerce Committee debated the issue [of drug pricing] at a heated hearing.  Read more on "Pharma Comes Under Fire for Jump in Rx Prices"

CBO Report Shows Hundreds Of Millions Spent On Direct Marketing Of Drugs To Consumers

The Congressional Budget Office released an "interesting report" on on how "pharmaceutical companies market prescription drugs, a subject that has received some scrutiny during the debate on ways to control health care spending," The New York Times reports. Among the most widely direct-to-consumer marketed medicines are erectile dysfunction aids, bone resorption inhibitors and a bevy of sleep aids, antidepressants, statins and antipsychotics. "Perhaps counterintuitively, the...

Patients Unlikely To Benefit From Free E-Samples Of Prescription Drugs

Search the Internet to learn about your asthma, high cholesterol or other common disorder, and odds are you'll be directed to a pharmaceutical company-sponsored Web homepage. There you'll often find an offer for a free sample or a one-time discount on a top-selling prescription medication. Is it a good deal? Not according to a study of such direct-to-consumer offers on the Internet by a research team led by Dr. William G. Weppner of the University of Washington (UW) Department...

Drug Ads Ineffective For Boosting Sales, Could Cost Taxpayers: UBC-Harvard Study

US Taxpayers may be on the hook for the high cost of drug advertising that does little to boost sales, according to a new study led by a University of British Columbia health policy researcher. The study, published in the Archives of Internal Medicine, examined the US sales patterns of clopidogrel, a top-selling...

Study: Direct-to-consumer drug ads can be misleading

Drugmakers have taken a lot of flack over direct-to-consumer drug advertising, but to date, Congress hasn't imposed any major limitations on the practice. Critics have argued that such ads encourage the use of costly new drugs over equally-effective generics. And those critics aren't going away anytime soon, it seems, especially if studies like these keep coming.The latest challenge to DTC drug ads comes from researchers with the University of California, Los Angeles. The...

Is diversification really such a great idea?

Datamonitor has struck a blow against diversification in pharma. The market research firm points out that many Big Pharma firms are putting more and more eggs in other baskets besides prescription drugs. And we all know that a distinct group of companies are relying on diversification to cushion the blow when pharma's biggest meds fall off the fast-approaching patent cliff. But the problem with that strategy, Datamonitor says, is that the margins on prescription drugs tend to be...

Pharma's Fourth Hurdle - Market Access

Getting regulatory agency approval for a new drug was once the end goal of pharmaceutical drug development, but in today's healthcare environment where governments increasingly determine price and the availability of drugs to patients through formulary designation, market access has become the "fourth hurdle" in successfully bringing a drug to market. "Before a drug is even approved, we need to be sure market access strategies are in place so that we can ensure profitability...

Pharmaceutical Manufacturers To Benefit From Consistency And Clarity

To improve key documentation relied upon by the pharmaceutical industry and others, the U.S. Pharmacopeial (USP) Convention announces the release of the redesigned United States Pharmacopeia-National Formulary (USP-NF). The new format brings consistency and clarity to language and formats used throughout the publication, greatly improving ease of use. USP has produced this book of written standards for the identity, quality, purity, and strength of medicines and their ingredients since...

New Tests For Identifying Potentially Deadly Adulterants In Pharmaceutical Ingredients

To further protect patients from adulterated medicines, the U.S. Pharmacopeial Convention (USP) has announced revised standards for four ingredients widely used in prescription and over-the-counter drugs. The standards, posted on the USP Web site, include new tests for identifying two harmful and potentially deadly contaminants in the four pharmaceutical excipients - inactive ingredients common in medicines for purposes including sweetening agents and solvents. USP is a...

Stimulus Grant To Help MSU Team Improve Drug Development From Plants

Scientists at Michigan State University are receiving nearly $3 million from the National Institutes of Health to uncover how several popular plants make medicinal compounds. The funding, part of a larger $6 million award via the American Recovery and Reinvestment Act, will provide scientists the resources to understand exactly which genes are involved in the synthesis of medicinal chemicals in several plants -- clearing the way for cheaper and more effective ways to produce...

Researchers Make Recommendations For Minimizing Harm And Maximizing Benefits Of Drug Ads

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA. "American television viewers see as many as 16 hours...

Pharma's Fourth Hurdle - Market Access

Getting regulatory agency approval for a new drug was once the end goal of pharmaceutical drug development, but in today's healthcare environment where governments increasingly determine price and the availability of drugs to patients through formulary designation, market access has become the "fourth hurdle" in successfully bringing a drug to market. "Before a drug is even approved, we need to be sure market access strategies are in place so that we can ensure profitability...

Can the Relationship Between Doctors and Drug Companies Ever Be a Healthy One?

Should the financial ties between doctors and drug companies be completely cut, or are healthy alliances between the two possible with the common aim of improving human health? A debate in this week's PLoS Medicine discusses whether the influence of drug company money on doctors is always a corrupting one.The relationship between doctors and drug companies has been the subject of intense scrutiny in recent years, with some commentators arguing that the public health...

Videos

Electronic Health Records 2.0: What Does the Future Hold?

This Expert voices panel focuses on Electronic Health Records 2.0, which aired on Federal News Radio (WFED) on February 28, 2012. Panelists include: Peter Basch, MD, FACP, Medical Director, Ambulatory EHR...

Main Video Page